Longwood Fund

Type

Venture Capital

Status

Active

Location

Boston, United States

Total investments

61

Average round size

53M

Portfolio companies

41

Rounds per year

4.36

Lead investments

6

Follow on index

0.33

Exits

14

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2010 was created Longwood Founders Fund, which is appeared as VC. The main office of represented VC is situated in the Boston. The fund was located in North America if to be more exact in United States.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight TScan Therapeutics, Colorescience, Channel Medsystems. Among the most popular fund investment industries, there are E-Commerce, Life Science. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The current fund was established by Christoph Westphal, Michelle Dipp, Richard Aldrich.

The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Longwood Founders Fund performs on 17 percentage points more the average number of lead investments. The high activity for fund was in 2019.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Longwood Founders Fund, startups are often financed by SV Health Investors, MPM Capital, Delphi Ventures. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Bessemer Venture Partners, Novartis Venture Fund. In the next rounds fund is usually obtained by MPM Capital, Vertex Ventures, Cardinal Partners.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life Sciences
Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 180000000
Fund raised date
2023-05-03

Analytics

Total investments
61
Lead investments
6
Exits
14
Rounds per year
4.36
Follow on index
0.33
Investments by industry
  • Biotechnology (53)
  • Health Care (26)
  • Therapeutics (22)
  • Pharmaceutical (21)
  • Life Science (18)
  • Show 25 more
Investments by region
  • United States (53)
  • United Kingdom (6)
  • Germany (1)
  • Italy (1)
Peak activity year
2021
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
236M
Group Appearance index
0.98
Avg. company exit year
7
Avg. multiplicator
4.13
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
DEM BioPharma 23 Jun 2022 Biotechnology, Life Science, Pharmaceutical Early Stage Venture 70M United States, Massachusetts, Cambridge
Progentos Therapeutics 20 May 2024 Early Stage Venture 65M United States, Massachusetts, Watertown

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.